Scarica l'app Stockscreener
1.76
5.38%
-0.10
Dopo l'orario di chiusura:
1.76
Telomir Pharmaceuticals Inc Borsa (TELO) Ultime notizie
TELO Rises on Promising Telomir-1 Preclinical Results - MSN
Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeriaan Ultra-Rare Genetic Disorder that Causes Rapid Aging - Knoxville News Sentinel
Telomir Pharmaceuticals reports positive results for progeria treatment By Investing.com - Investing.com South Africa
# Telomir-1 shows anti-aging effects in progeria cell study By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals reports positive results for progeria treatment - Investing.com
# Telomir-1 shows anti-aging effects in progeria cell study - Investing.com Australia
Telomir Pharmaceuticals IncTelomir-1 Significantly Increased Cell ViabilitySEC Filing - MarketScreener
Revolutionary Progeria Treatment Shows First-Ever Cellular Aging Prevention in Children's Cells - Stock Titan
EXCLUSIVE: Telomir Pharmaceuticals Says Preclinical Drug Candidate Prevents Premature Aging In Patient-Derived Cells From Children With Progeria - Benzinga
10 Best Growth Stocks Under $100 to Buy Now - Insider Monkey
Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model - The Oklahoman
Telomir-1 shows promise in reversing Wilson’s disease symptoms By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports promising drug trial results By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports promising drug trial results - Investing.com
Telomir Pharmaceuticals Says Positive Preclinical Results For Telomir-1 In Wilson'S Disease Animal Model - MarketScreener
Telomir-1 shows promise in reversing Wilson’s disease symptoms - Investing.com Australia
Breakthrough Wilson's Disease Treatment Reverses Brain, Liver, and Kidney Damage in Preclinical Study - Stock Titan
Nuveen Asset Management LLC Purchases New Shares in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome - Reno Gazette Journal
telomir pharmaceuticals reports promising preclinical results for telomir-1 By Investing.com - Investing.com South Africa
EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder - AOL.com
Telomir Says Lead Candidate Telomir-1 Restored Gene Regulation in Animal Model of Werner Syndrome - MarketScreener
telomir pharmaceuticals reports promising preclinical results for telomir-1 - Investing.com
Telomir Pharmaceuticals-New Data From Preclinical Study Of Its Lead Compound, Telomir-1, In Validated Animal Model Of Werner Syndrome - marketscreener.com
Revolutionary Anti-Aging Drug Resets Biological Clock, Reverses Multiple Aging Markers in Landmark Study - Stock Titan
Telomir Pharmaceuticals Joins BIO Convention for Partnerships - MSN
Telomir announces positive preclinical data for its novel oral AMD therapeutic - Ophthalmology Times
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Increases Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform - Cheboygan Daily Tribune
Telomir Pharmaceuticals To Present At BIO 2025, Eyes IND Filing For Telomir-1 - Nasdaq
Revolutionary Anti-Aging Drug Telomir-1 Heads to FDA Review: Multiple Disease Applications Revealed - Stock Titan
2.13%
1.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):